{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T09:57:59Z","timestamp":1769939879987,"version":"3.49.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.phrs.2008.11.004","type":"journal-article","created":{"date-parts":[[2008,11,28]],"date-time":"2008-11-28T10:46:32Z","timestamp":1227869192000},"page":"90-100","source":"Crossref","is-referenced-by-count":33,"title":["Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy"],"prefix":"10.1016","volume":"59","author":[{"given":"Corrado","family":"Blandizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Tuccori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocchina","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Fornai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Antonioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narcisa","family":"Ghisu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Del Tacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2008.11.004_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.gastro.2008.05.030","article-title":"Gastric mucosal defense and cytoprotection: bench to bedside","volume":"135","author":"Laine","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib2","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/gast.2002.36013","article-title":"Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcome study in patients with rheumatoid arthritis","volume":"123","author":"Laine","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.phrs.2008.11.004_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/00002018-200629020-00002","article-title":"NSAID-associated adverse effects and acid control aids to prevent them","volume":"29","author":"Naesdal","year":"2006","journal-title":"Drug Safety"},{"key":"10.1016\/j.phrs.2008.11.004_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002512-200825030-00003","article-title":"Clinical efficacy of esomeprazole in the prevention and healing of digestive toxicity associated with non-steroidal anti-inflammatory drugs in elderly patients","volume":"25","author":"Blandizzi","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.phrs.2008.11.004_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.phrs.2008.11.004_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0269-2813.2004.01834.x","article-title":"Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclooxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy","volume":"19","author":"Dubois","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.11.004_bib8","first-page":"96","article-title":"Gastrointestinal safety of novel nonsteroidal anti-inflammatory drugs: selective COX-2 inhibitors and beyond","volume":"78","author":"Coruzzi","year":"2007","journal-title":"Acta Biomed"},{"key":"10.1016\/j.phrs.2008.11.004_bib9","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0022-3565(25)24061-7","article-title":"Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases","volume":"271","author":"Patrignani","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2008.11.004_bib10","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis","volume":"96","author":"Warner","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2008.11.004_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI200113418","article-title":"Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs","volume":"108","author":"Patrono","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2008.11.004_bib12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1185\/030079902125001335","article-title":"The selectivity of novel COX-2 inhibitors in human whole blood assays of COX-isozyme activity","volume":"18","author":"Tacconelli","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.phrs.2008.11.004_bib13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1096\/fj.03-0645rev","article-title":"Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic","volume":"18","author":"Warner","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.phrs.2008.11.004_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.prostaglandins.2006.05.019","article-title":"Pharmacodynamic of cyclooxygenase inhibitors in humans","volume":"82","author":"Capone","year":"2007","journal-title":"Prostaglandins other Lipid Mediat"},{"key":"10.1016\/j.phrs.2008.11.004_bib15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2174\/1381612013397663","article-title":"Antiinflammatory agents less dangerous for gastrointestinal tract","volume":"7","author":"Rodriguez-Tellez","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.phrs.2008.11.004_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1472-8206.2003.00135.x","article-title":"Gastrointestinal effects of nonsteroidal anti-inflammatory drugs","volume":"17","author":"Whittle","year":"2002","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.phrs.2008.11.004_bib17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/10715760410001705168","article-title":"Role of L-arginine in ibuprofen-induced oxidative stress and neutrophil infiltration in gastric mucosa","volume":"38","author":"Jim\u00e8nez","year":"2004","journal-title":"Free Radic Res"},{"key":"10.1016\/j.phrs.2008.11.004_bib18","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1152\/ajpcell.00102.2004","article-title":"Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin","volume":"288","author":"Allen","year":"2005","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.phrs.2008.11.004_bib19","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/gast.1997.v113.pm9352857","article-title":"Roles of prostaglandin E-receptor subtypes in gastric and duodenal bicarbonate secretion in rats","volume":"113","author":"Takeuchi","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0016-5085(99)70503-2","article-title":"Na+\/HCO3\u2212 cotransport and expression of NBC1 and NBC2 in rabbit gastric parietal and mucous cells","volume":"116","author":"Rossmann","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.gastro.2004.04.003","article-title":"The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice","volume":"127","author":"Darling","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.bjp.0707176","article-title":"Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin","volume":"150","author":"Lichtenberger","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2008.11.004_bib23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0006-2952(00)00576-1","article-title":"Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited","volume":"61","author":"Lichtenberger","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.phrs.2008.11.004_bib24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/bega.2001.0229","article-title":"Pathogenesis of NSAID-induced gastroduodenal mucosal injury","volume":"15","author":"Wallace","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.phrs.2008.11.004_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2036.2007.03348.x","article-title":"Determinants of the short-term gastric damage caused by NSAIDs in man","volume":"26","author":"Bjarnason","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.11.004_bib26","doi-asserted-by":"crossref","first-page":"C1213","DOI":"10.1152\/ajpcell.00558.2003","article-title":"The tight junction: a multifunctional complex","volume":"286","author":"Schneeberger","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2008.11.004_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2036.18.s1.15.x","article-title":"The protective effect of rebamipide on paracellular permeability of rat gastric epithelial cells","volume":"18","author":"Joh","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.11.004_bib28","doi-asserted-by":"crossref","first-page":"C800","DOI":"10.1152\/ajpcell.00157.2008","article-title":"Aspirin induces gastric epithelial barrier dysfunction by activating p38 MAPK via claudin-7","volume":"295","author":"Oshima","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.phrs.2008.11.004_bib29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1124\/mol.54.3.536","article-title":"Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa","volume":"54","author":"Zimmermann","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2008.11.004_bib30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0092-8674(95)90126-4","article-title":"Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration","volume":"83","author":"Langenbach","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2008.11.004_bib31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/gast.2000.16510","article-title":"NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2","volume":"119","author":"Wallace","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1100\/tsw.2006.122","article-title":"COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation","volume":"6","author":"Wallace","year":"2006","journal-title":"Scientific World J"},{"key":"10.1016\/j.phrs.2008.11.004_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.bjp.0706201","article-title":"Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense","volume":"145","author":"Wallace","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2008.11.004_bib34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1096\/fj.02-0770com","article-title":"Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense","volume":"17","author":"Devchand","year":"2003","journal-title":"FASEB J"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2008.11.004_bib35","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1007\/s10620-005-2803-6","article-title":"Cellular and molecular mechanisms of gastrointestinal ulcer healing","volume":"50","author":"Tarnawski","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.phrs.2008.11.004_bib36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.49.3.443","article-title":"Cyclooxygenase 2\u2014implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives","volume":"49","author":"Halter","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2008.11.004_bib37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/gast.1997.v112.pm9024292","article-title":"Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice","volume":"112","author":"Mizuno","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib38","doi-asserted-by":"crossref","first-page":"G788","DOI":"10.1152\/ajpgi.00131.2007","article-title":"Cyclooxygenase-2\/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors","volume":"293","author":"Hatazawa","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.phrs.2008.11.004_bib39","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/gut.47.6.762","article-title":"Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa","volume":"47","author":"Jackson","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2008.11.004_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2036.2001.00889.x","article-title":"Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer","volume":"15","author":"To","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.11.004_bib41","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0022-3565(24)37734-1","article-title":"Role of cyclooxygenase-2 in the healing of gastric ulcers in rats","volume":"286","author":"Shigeta","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2008.11.004_bib42","doi-asserted-by":"crossref","first-page":"G747","DOI":"10.1152\/ajpgi.00416.2005","article-title":"Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice","volume":"290","author":"Schmassmann","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2008.11.004_bib43","first-page":"A738","article-title":"NSAID activated gene (NAG-1) plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer repair","volume":"134","author":"Colucci","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib44","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejphar.2004.07.042","article-title":"Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors","volume":"500","author":"Whittle","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.phrs.2008.11.004_bib45","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/BF00920471","article-title":"Mechanisms of acute and chronic intestinal inflammation induced by indomethacin","volume":"17","author":"Yamada","year":"1993","journal-title":"Inflammation"},{"key":"10.1016\/j.phrs.2008.11.004_bib46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0090-6980(77)90178-2","article-title":"Resistance of germfree rats to indomethacin-induced intestinal lesions","volume":"14","author":"Robert","year":"1977","journal-title":"Prostaglandins"},{"key":"10.1016\/j.phrs.2008.11.004_bib47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0014-2999(01)01327-9","article-title":"Interactive roles of superoxide and inducible nitric oxide synthase in rat intestinal injury provoked by non-steroidal anti-inflammatory drugs","volume":"429","author":"Evans","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.phrs.2008.11.004_bib48","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/0006-2952(75)90450-5","article-title":"Enterohepatic circulation of indomethacin and its role in intestinal irritation","volume":"24","author":"Duggan","year":"1975","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.phrs.2008.11.004_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0016-5085(97)70225-7","article-title":"Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation","volume":"112","author":"Reuter","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib50","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.clinbiochem.2007.01.015","article-title":"Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts","volume":"40","author":"Petruzzelli","year":"2007","journal-title":"Clin Biochem"},{"key":"10.1016\/j.phrs.2008.11.004_bib51","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2982.2006.00795.x","article-title":"Constitutive expression of cyclooxygenase-2 in the neuromuscular compartment of normal human colon","volume":"18","author":"Bernardini","year":"2006","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.phrs.2008.11.004_bib52","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1124\/jpet.102.041715","article-title":"Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events","volume":"303","author":"Tanaka","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2008.11.004_bib53","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/gast.2002.33647","article-title":"COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice","volume":"122","author":"Sigthorsson","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejphar.2006.08.089","article-title":"Intestinal effects of nonselective and selective cyclooxygenase inhibitors in the rat","volume":"552","author":"Menozzi","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.phrs.2008.11.004_bib55","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial","volume":"284","author":"Silverstein","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.phrs.2008.11.004_bib56","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2008.11.004_bib57","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7326\/0003-4819-139-7-200310070-00005","article-title":"Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial","volume":"139","author":"Lisse","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.phrs.2008.11.004_bib58","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2008.11.004_bib59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.amjmed.2005.09.054","article-title":"Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study","volume":"119","author":"Singh","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.phrs.2008.11.004_bib60","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0140-6736(07)60234-7","article-title":"Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison","volume":"369","author":"Laine","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2008.11.004_bib61","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.dld.2007.04.002","article-title":"COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do?","volume":"39","author":"Lazzaroni","year":"2007","journal-title":"Dig Liv Dis"},{"key":"10.1016\/j.phrs.2008.11.004_bib62","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1053\/j.gastro.2007.06.058","article-title":"Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxib","volume":"133","author":"Ray","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0140-6736(07)60206-2","article-title":"Do COX-2 inhibitors give enough gastrointestinal protection?","volume":"369","author":"Drenth","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2008.11.004_bib64","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","article-title":"Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison","volume":"354","author":"Emery","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2008.11.004_bib65","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","article-title":"A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group","volume":"117","author":"Laine","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib66","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cgh.2007.03.011","article-title":"Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review","volume":"5","author":"Rostom","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.phrs.2008.11.004_bib67","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bmj.331.7528.1310","article-title":"Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis","volume":"331","author":"Hippisley-Cox","year":"2005","journal-title":"Br Med J"},{"key":"10.1016\/j.phrs.2008.11.004_bib68","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1053\/j.gastro.2006.12.007","article-title":"Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population","volume":"132","author":"Garcia-Rodriguez","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib69","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.cgh.2006.08.016","article-title":"Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications","volume":"4","author":"Goldstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2008.11.004_bib70","first-page":"S54","article-title":"Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol","volume":"31","author":"Koch","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"10.1016\/j.phrs.2008.11.004_bib71","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archinte.162.2.169","article-title":"Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole","volume":"162","author":"Graham","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.phrs.2008.11.004_bib72","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management","volume":"338","author":"Hawkey","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2008.11.004_bib73","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","article-title":"A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group","volume":"338","author":"Yeomans","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2008.11.004_bib74","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1053\/j.gastro.2007.11.016","article-title":"The called-for large clinical trial is already ongoing","volume":"134","author":"Peura","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib75","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.gastro.2008.01.010","article-title":"The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs","volume":"134","author":"Targonwik","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00002512-200724020-00004","article-title":"Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly","volume":"24","author":"Lanas","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1016\/j.phrs.2008.11.004_bib77","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/gut.2005.080754","article-title":"Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations","volume":"55","author":"Lanas","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2008.11.004_bib78","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.gastro.2004.05.001","article-title":"Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial","volume":"127","author":"Laine","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib79","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/j.1365-2036.2006.02912.x","article-title":"The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor","volume":"23","author":"Goldstein","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.11.004_bib80","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10620-007-9903-4","article-title":"Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81mg q.d.) alone or coadministered with celecoxib or naproxen: a randomised. 1-week trial","volume":"53","author":"Goldstein","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.phrs.2008.11.004_bib81","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2004.01935.x","article-title":"Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications\u2014review and recommendations based on risk assessment","volume":"19","author":"Chan","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 4","key":"10.1016\/j.phrs.2008.11.004_bib82","first-page":"S33","article-title":"Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs: nice or necessary?","volume":"4","author":"Laine","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"key":"10.1016\/j.phrs.2008.11.004_bib83","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.cgh.2007.06.009","article-title":"Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial","volume":"5","author":"Goldstein","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.phrs.2008.11.004_bib84","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa021907","article-title":"Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis","volume":"347","author":"Chan","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2008.11.004_bib85","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1053\/j.gastro.2004.07.010","article-title":"Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial","volume":"127","author":"Chan","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib86","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.amjmed.2005.04.031","article-title":"Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications","volume":"118","author":"Lai","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.phrs.2008.11.004_bib87","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1572-0241.2005.41465.x","article-title":"Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors","volume":"100","author":"Hawkey","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.phrs.2008.11.004_bib88","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1572-0241.2006.00499.x","article-title":"Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors","volume":"101","author":"Scheiman","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.phrs.2008.11.004_bib89","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(07)60749-1","article-title":"Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomized trial","volume":"369","author":"Chan","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2008.11.004_bib90","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/pgmj.2005.039586","article-title":"Is nonsteroidal antiinflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?","volume":"82","author":"Adebayo","year":"2006","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.phrs.2008.11.004_bib91","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2036.2006.03043.x","article-title":"Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs","volume":"24","author":"Laine","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.11.004_bib92","first-page":"134","article-title":"Nonsteroidal anti-inflammatory drugs and the small intestine","volume":"23","author":"Fortun","year":"2007","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.phrs.2008.11.004_bib93","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1542-3565(03)70031-7","article-title":"Ulcerative ileitis encountered at ileo-colonscopy: likely role of nonsteroidal agents","volume":"1","author":"Lengeling","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.phrs.2008.11.004_bib94","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1542-3565(04)00603-2","article-title":"Visible small-intestinal mucosal injury in chronic NSAID users","volume":"3","author":"Graham","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.phrs.2008.11.004_bib95","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1053\/j.gastro.2005.03.020","article-title":"A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy","volume":"128","author":"Maiden","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib96","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1542-3565(04)00619-6","article-title":"Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo","volume":"3","author":"Goldstein","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.phrs.2008.11.004_bib97","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2007.03312.x","article-title":"Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy","volume":"25","author":"Goldstein","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.11.004_bib98","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/gast.2003.50054","article-title":"Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use","volume":"124","author":"Laine","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib99","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","article-title":"Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison","volume":"368","author":"Cannon","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2008.11.004_bib100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2036.2006.02745.x","article-title":"Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?","volume":"23","author":"Nielsen","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.11.004_bib101","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.amjmed.2008.01.045","article-title":"Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs","volume":"121","author":"Jones","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.phrs.2008.11.004_bib102","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0140-6736(08)60137-3","article-title":"COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs","volume":"371","author":"Warner","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2008.11.004_bib103","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1368-5031.2005.00660.x","article-title":"Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage","volume":"59","author":"Singh","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.phrs.2008.11.004_bib104","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.coph.2004.08.003","article-title":"Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs","volume":"4","author":"Whittle","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.phrs.2008.11.004_bib105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/156802607779941350","article-title":"Cyclo-oxygenase (COX) inhibiting nitric oxide donating (CINODs) drugs: a review of their current status","volume":"7","author":"Fiorucci","year":"2007","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.phrs.2008.11.004_bib106","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1572-0241.2004.04133.x","article-title":"The gastrointestinal tolerability of the LOX\/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial","volume":"99","author":"Bias","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.phrs.2008.11.004_bib107","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2125.2004.02198.x","article-title":"Current approaches to prevent NSAID-induced gastropathy\u2014COX selectivity and beyond","volume":"58","author":"Becker","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2008.11.004_bib108","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/j.1572-0241.1999.01211.x","article-title":"Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects","volume":"94","author":"Anand","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.phrs.2008.11.004_bib109","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1053\/gast.2003.50096","article-title":"Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study","volume":"124","author":"Fiorucci","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2008.11.004_bib110","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/gut.52.11.1537","article-title":"Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans","volume":"52","author":"Hawkey","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2008.11.004_bib111","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/00365520510024197","article-title":"Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects","volume":"41","author":"Wilder-Smith","year":"2006","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.phrs.2008.11.004_bib112","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/ard.2004.023572","article-title":"A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis","volume":"64","author":"Lohmander","year":"2005","journal-title":"Ann Rheum Dis"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661808002181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661808002181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T23:12:50Z","timestamp":1738710770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661808002181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S1043661808002181"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2008.11.004","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}